A new immuno-oncology combination from Bristol Myers Squibb (NYSE: BMY) and Exelixis (Nasdaq: EXEL) could make a real difference in kidney cancer, the firms outlined on Saturday.
Detailed results from CheckMate -9ER, presented at the annual congress of the European Society of Medical Oncology (ESMO), expand on top-line data released earlier in the year.
The firms hope to be able to offer an effective alternative to existing I-O combinations which pair Pfizer’s (PFE: NYSE) tyrosine kinase inhibitor (TKI) Inlyta (axitinib) with a checkpoint blocker.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze